Sol Gel Technologies Ltd (SLGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sol Gel Technologies Ltd (SLGL) has a cash flow conversion efficiency ratio of 0.045x as of December 2022. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.89 Million) by net assets ($42.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see SLGL company net worth for the company's overall valuation and market capitalisation.
Sol Gel Technologies Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Sol Gel Technologies Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sol Gel Technologies Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sol Gel Technologies Ltd ranked by their cash flow conversion efficiency. Explore SLGL cash flow quality index to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nishoku Technology Inc
TW:3679
|
0.060x |
|
Dongwha Enterprise Co.Ltd
KQ:025900
|
0.003x |
|
Azkoyen
MC:AZK
|
0.141x |
|
Draganfly Inc
NASDAQ:DPRO
|
-0.092x |
|
Microvast Holdings Inc
NASDAQ:MVST
|
0.009x |
|
Greenx Metals Ltd
AU:GRX
|
-0.223x |
|
Volati AB
ST:VOLO
|
-0.060x |
|
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
NASDAQ:OACC
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Sol Gel Technologies Ltd (2014–2025)
The table below shows the annual cash flow conversion efficiency of Sol Gel Technologies Ltd from 2014 to 2025. View SLGL live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $22.81 Million | $322.00K | 0.014x | +102.93% |
| 2024-12-31 | $28.85 Million | $-13.89 Million | -0.481x | -4.93% |
| 2023-12-31 | $38.64 Million | $-17.73 Million | -0.459x | -104.21% |
| 2022-12-31 | $42.21 Million | $-9.48 Million | -0.225x | -62.40% |
| 2021-12-31 | $55.59 Million | $-7.69 Million | -0.138x | +72.13% |
| 2020-12-31 | $50.85 Million | $-25.24 Million | -0.496x | -15.75% |
| 2019-12-31 | $52.47 Million | $-22.50 Million | -0.429x | -16.79% |
| 2018-12-31 | $63.91 Million | $-23.47 Million | -0.367x | -180.33% |
| 2017-12-31 | $-52.70 Million | $-24.09 Million | 0.457x | -22.55% |
| 2016-12-31 | $-31.34 Million | $-18.50 Million | 0.590x | -15.49% |
| 2015-12-31 | $-11.52 Million | $-8.04 Million | 0.698x | -67.11% |
| 2014-12-31 | $-2.27 Million | $-4.83 Million | 2.123x | -- |
About Sol Gel Technologies Ltd
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treat… Read more